within Pharmacolibrary.Drugs.ATC.J;

model J05AR11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.36666666666666664,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.0013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>A fixed-dose combination antiretroviral medication containing lamivudine (a nucleoside reverse transcriptase inhibitor), tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor), and efavirenz (a non-nucleoside reverse transcriptase inhibitor). This combination is used in the treatment of HIV-1 infection and is approved for use as part of antiretroviral therapy (ART) regimens.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after single oral administration of the co-formulated fixed-dose tablet.</p><h4>References</h4><ol><li><p>Liu, H, et al., &amp; Fletcher, CV (2020). Pharmacokinetics of Coencapsulated Antiretrovirals with Ingestible Sensors. <i>AIDS research and human retroviruses</i> 36(1) 65–74. DOI:<a href=&quot;https://doi.org/10.1089/AID.2019.0202&quot;>10.1089/AID.2019.0202</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31516025/&quot;>https://pubmed.ncbi.nlm.nih.gov/31516025</a></p></li><li><p>Bednasz, CJ, et al., &amp; Morse, GD (2019). Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202. <i>Antimicrobial agents and chemotherapy</i> 63(4) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.01638-18&quot;>10.1128/AAC.01638-18</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30642925/&quot;>https://pubmed.ncbi.nlm.nih.gov/30642925</a></p></li><li><p>Pozniak, AL, et al., &amp; Muirhead, GJ (2008). A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. <i>British journal of clinical pharmacology</i> 65 Suppl 1(Suppl 1) 54–59. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2008.03136.x&quot;>10.1111/j.1365-2125.2008.03136.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18333866/&quot;>https://pubmed.ncbi.nlm.nih.gov/18333866</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AR11;
